MIME-improvement programs IEMAD the treatment of refractory and relapsed non-Hodgkins lymphoma.doc

 PAGE \* MERGEFORMAT 6 MIME-improvement programs IEMAD the treatment of refractory and relapsed non-Hodgkin’s lymphoma Author: Hong-Hua Li, Xiao-Xiong Wu, Wang Transit, Zhao Yu, Jian Bo, Wang Shu-Hong, Wan-Ming Da, Yu Li [Abstract] In order to explore the improvement MIME program-IEMAD (ifosfamide, VM26 or VP16, methotrexate, cytarabine, dexamethasone or methylprednisolone) in treatment of refractory and (or) recurrent non-Hodgkin’s lymphoma (NHL) of the efficacy, using the program has treated 25 cases of refractory and (or) of recurrent NHL patients, including refractory NHL 11 patients with recurrent NHL 14 Li. The results showed that: 6 patients with refractory and (or) of recurrent NHL patients achieved complete remission (CR rate 24.0%), 7 patients achieved partial remission (PR rate was 28.0%), total effective rate was 52.0%, median survival period of 13 months, with a median disease-free time to progression was 8 months; IEMAD in the treatment of toxic side effects of mild adverse reactions, mainly gastrointestinal discomfort and bone marrow suppression, no treatment-related deaths occurred. Conclusion: MIME improvement program IEMAD For some refractory and (or) of recurrent non-Hodgkin’s lymphoma (NHL) is effective and less toxic side effects, the patient is well tolerated. Can be used for other treatment programs have been ineffective in refractory and (or) of recurrent non-Hodgkin’s lymphoma (NHL) in patients with treatment. [Keywords:] non-Hodgkin’s lymphoma IEMAD (Modified MIME) Therapy for Refractory or Relapsed Non-Hodgkin ‘s Lymphoma Abstract The study was aimed to evaluate the effect of IEMAD (modified MIME) composed of isofosfamide, VM26 or VP16, methotrexate, cytarabine, dexamethasone or methylprednisolone, in treatment of refractory or relapsed non-Hodgkin ‘s lymphoma. Twenty-five patients with refractory or relapsed non-Hodgkin’s lymphoma (11 refractory NHL patients, 14 relapsed NHL patients) were treated with IEMAD regimen.The result